Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008
News Dec 13, 2007
Rosetta Genomics, Ltd. has announced that it has selected the technological platform for its line of microRNA-based diagnostic products, the first of which are expected to launch in 2008.
The company has licensed the MGB Probe technology from Nanogen, Inc. The licensing deal will allow Rosetta Genomics to combine the technical performance advantages of Nanogen's MGB Probe technology with the Company's own proprietary microRNA biomarkers to create a line of quantitative real-time PCR diagnostic tests.
Leveraging microRNAs' tissue specificity and involvement in the regulation of a large number of human genes, Rosetta Genomics has identified specific microRNA signatures that it believes will allow for accurate diagnosis of various cancers.
The Company expects the following three tests to launch in 2008:
• Differentiating squamous from non squamous lung cancer - As current targeted therapy for lung cancer can cause hemorrhaging in squamous cell lung cancer patients, differentiating between the cancer types is critical. Rosetta Genomics has identified several microRNA biomarkers that may allow for sensitive and specific identification of squamous cell carcinoma.
• Differentiating mesothelioma from lung adenocarcinoma - Rosetta Genomics has identified a panel of microRNA biomarkers potentially allowing for differentiation between these cancer types.
• Cancer of Unknown Primary (CUP) - This test is designed to assist clinicians to identify the origin of metastases. Rosetta Genomics has developed a panel of microRNA biomarkers potentially able to identify approximately thirty cancers.
"Our proprietary microRNA detectionn and quantitation technologies are at the heart of our sensitive diagnostic products," noted Amir Avniel, President and CEO of Rosetta Genomics."
“Using very small amounts of tissue samples or body fluids, we are able to detect microRNAs on the order of single molecules, as well as differentiate microRNAs with only a single nucleotide mismatch. We look forward to the launch of our first diagnostic products in 2008."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.